ALKERMES OVER-ALLOTMENT FULLY EXERCISED
ALKERMES OVER-ALLOTMENT FULLY EXERCISED CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- Alkermes, Inc.
(NASDAQ: ALKS) today announced that the underwriters of the company's recently completed public offering have fully exercised their option to purchase 300,000 additional shares of common stock to cover over-allotments from the offering.
As a result of the purchase of the shares by the underwriters, managed by Robertson, Stephens & Company (San Francisco) and J.P. Morgan Securities Inc. (New York), a total of 2.3 million shares, including the over-allotment, were sold through the offering at a price to the public of $17.50 per share. Alkermes, Inc. is a neuropharmaceutical company founded in 1987 that is focused on the development and commercialization of therapeutic and diagnostic products for the treatment of disorders of the central nervous system. Copies of the prospectus relating to the offering may be obtained from Robertson, Stephens & Company, One Embarcadero Center, 31st Floor, San Francisco, CA 94111, or J.P. Morgan Securities Inc., 60 Wall St., New York, N.Y. 10260. -0- 11/20/91 /CONTACT: Michael J. Landine, chief financial officer of Alkermes, 617-494-0171, or Thomas A. Pearson of Pearson Communications, 215-648-3975, for Alkermes/ (ALKS) CO: Alkermes, Inc. ST: Massachusetts IN: MTC SU:
SH -- NE009 -- 5408 11/20/91 12:13 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 20, 1991|
|Previous Article:||AMERICAN HOME PRODUCTS AND ALZA ENTER JOINT RESEARCH, DEVELOPMENT AND MARKETING AGREEMENT|
|Next Article:||INTERMAGNETICS GENERAL AWARDED PROGRAM TO DESIGN MOTOR FOR MAGLEV VEHICLE|